Related Experiment Video

Updated: Jul 17, 2026

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Abeta40 inhibits amyloid deposition in vivo

Jungsu Kim1, Luisa Onstead, Suzanne Randle

  • 1Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida 32224, USA.

The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|January 20, 2007
PubMed

Insights

Alzheimer's disease research reveals amyloid beta 42 (Abeta42) promotes amyloid deposition, while amyloid beta 40 (Abeta40) inhibits it. Increasing Abeta40 levels may protect against Alzheimer's disease progression.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Alzheimer's disease (AD) pathogenesis is strongly linked to amyloid beta 42 (Abeta42).
  • Amyloid beta 40 (Abeta40) is the predominant form of amyloid beta (Abeta) but its role in AD is unclear.
  • It is generally assumed that increased Abeta40 accelerates amyloid plaque formation.

Purpose of the Study:

  • To investigate the role of Abeta40 in Alzheimer's disease pathogenesis.
  • To determine the contrasting effects of Abeta40 and Abeta42 on amyloid deposition.
  • To assess the impact of increased Abeta40 levels on AD-related phenotypes.

Main Methods:

  • Generation of bitransgenic mice expressing high levels of Abeta40 (BRI-Abeta40 mice) crossed with Tg2576 and BRI-Abeta42A mice.
  • Analysis of parenchymal and cerebrovascular Abeta deposition in bitransgenic and singly transgenic littermates.
  • Evaluation of the premature-death phenotype in Tg2576 mice and its modulation by Abeta40.

Main Results:

  • Increased steady-state levels of Abeta40 significantly decreased Abeta deposition by 60-90% in bitransgenic mice.
  • Abeta42 was found to promote amyloid deposition, whereas Abeta40 demonstrated an inhibitory effect.
  • Elevated Abeta40 levels conferred protection against the premature-death phenotype observed in Tg2576 mice.

Conclusions:

  • Abeta42 and Abeta40 exhibit opposing roles in amyloid deposition, with Abeta42 promoting and Abeta40 inhibiting it.
  • Strategies targeting Abeta40 might worsen AD, while increasing Abeta40 could potentially reduce AD risk.
  • These findings highlight the complex role of different Abeta isoforms in Alzheimer's disease and suggest novel therapeutic avenues.

More Related Videos

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...